评估和修改花生过敏管理的共同决策工具

IF 5.4 2区医学 Q1 ALLERGY

Current Allergy and Asthma Reports Pub Date : 2024-04-19 DOI:10.1007/s11882-024-01146-w

Aikaterini Anagnostou, Andrew Yaworsky, Monica Brova, Nazifa Ibrahim, Siddharth Kakked, Sasha Spite, Linette Duluc, Alan L. Shields, Tricia Lee, Stephanie Leonard, Kathy Przywara, Amelia Smith

{"title":"评估和修改花生过敏管理的共同决策工具","authors":"Aikaterini Anagnostou, Andrew Yaworsky, Monica Brova, Nazifa Ibrahim, Siddharth Kakked, Sasha Spite, Linette Duluc, Alan L. Shields, Tricia Lee, Stephanie Leonard, Kathy Przywara, Amelia Smith","doi":"10.1007/s11882-024-01146-w","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Based on shared decision-making (SDM) principles, a decision aid was previously developed to help patients, their caregivers, and physicians decide which peanut allergy management approach best suits them. This study refined the decision aid’s content to better reflect patients’ and caregivers’ lived experience.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Current standard of care for peanut allergy is avoidance, although peanut oral immunotherapy has been approved by the Food and Drug Administration for use in patients 4–17 years old.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>An advisory board of allergy therapy experts (<i>n</i> = 3) and patient advocates (<i>n</i> = 3) informed modifications to the decision aid. The revised tool underwent cognitive debriefing interviews (CDIs) among adolescents (12–17 years old) with peanut allergy and caregivers of patients 4–17 years old with peanut allergy to evaluate its relevance, understandability, and usefulness. The 20 CDI participants understood the information presented in the SDM tool and reported it was important and relevant. Some revisions were made based on participant feedback. Results support content validity of the Peanut Allergy Treatment SDM Tool.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"94 1","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management\",\"authors\":\"Aikaterini Anagnostou, Andrew Yaworsky, Monica Brova, Nazifa Ibrahim, Siddharth Kakked, Sasha Spite, Linette Duluc, Alan L. Shields, Tricia Lee, Stephanie Leonard, Kathy Przywara, Amelia Smith\",\"doi\":\"10.1007/s11882-024-01146-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Purpose of Review</h3><p>Based on shared decision-making (SDM) principles, a decision aid was previously developed to help patients, their caregivers, and physicians decide which peanut allergy management approach best suits them. This study refined the decision aid’s content to better reflect patients’ and caregivers’ lived experience.</p><h3 data-test=\\\"abstract-sub-heading\\\">Recent Findings</h3><p>Current standard of care for peanut allergy is avoidance, although peanut oral immunotherapy has been approved by the Food and Drug Administration for use in patients 4–17 years old.</p><h3 data-test=\\\"abstract-sub-heading\\\">Summary</h3><p>An advisory board of allergy therapy experts (<i>n</i> = 3) and patient advocates (<i>n</i> = 3) informed modifications to the decision aid. The revised tool underwent cognitive debriefing interviews (CDIs) among adolescents (12–17 years old) with peanut allergy and caregivers of patients 4–17 years old with peanut allergy to evaluate its relevance, understandability, and usefulness. The 20 CDI participants understood the information presented in the SDM tool and reported it was important and relevant. Some revisions were made based on participant feedback. Results support content validity of the Peanut Allergy Treatment SDM Tool.</p>\",\"PeriodicalId\":55198,\"journal\":{\"name\":\"Current Allergy and Asthma Reports\",\"volume\":\"94 1\",\"pages\":\"\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Allergy and Asthma Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11882-024-01146-w\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Allergy and Asthma Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11882-024-01146-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

摘要

综述目的基于共同决策（SDM）原则，以前曾开发过一种决策辅助工具，帮助患者、其护理人员和医生决定哪种花生过敏管理方法最适合他们。本研究对辅助决策工具的内容进行了改进，以更好地反映患者和护理人员的生活经验。摘要由过敏治疗专家（3 人）和患者权益倡导者（3 人）组成的咨询委员会为辅助决策工具的修改提供了依据。修订后的工具在患有花生过敏症的青少年（12-17 岁）和 4-17 岁花生过敏症患者的护理人员中进行了认知汇报访谈 (CDI)，以评估其相关性、可理解性和实用性。20 位 CDI 参与者理解了 SDM 工具中提供的信息，并表示这些信息非常重要且具有相关性。根据参与者的反馈意见，对该工具进行了一些修订。结果支持花生过敏治疗 SDM 工具的内容有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management

查看原文本刊更多论文

Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management

Purpose of Review

Based on shared decision-making (SDM) principles, a decision aid was previously developed to help patients, their caregivers, and physicians decide which peanut allergy management approach best suits them. This study refined the decision aid’s content to better reflect patients’ and caregivers’ lived experience.

Recent Findings

Current standard of care for peanut allergy is avoidance, although peanut oral immunotherapy has been approved by the Food and Drug Administration for use in patients 4–17 years old.

Summary

An advisory board of allergy therapy experts (n = 3) and patient advocates (n = 3) informed modifications to the decision aid. The revised tool underwent cognitive debriefing interviews (CDIs) among adolescents (12–17 years old) with peanut allergy and caregivers of patients 4–17 years old with peanut allergy to evaluate its relevance, understandability, and usefulness. The 20 CDI participants understood the information presented in the SDM tool and reported it was important and relevant. Some revisions were made based on participant feedback. Results support content validity of the Peanut Allergy Treatment SDM Tool.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Allergy and Asthma Reports 医学-过敏

CiteScore

11.20

自引率

1.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of Current Allergy and Asthma Reports is to systematically provide the views of highly selected experts on current advances in the fields of allergy and asthma and highlight the most important papers recently published. All reviews are intended to facilitate the understanding of new advances in science for better diagnosis, treatment, and prevention of allergy and asthma. We accomplish this aim by appointing international experts in major subject areas across the discipline to review select topics emphasizing recent developments and highlighting important new papers and emerging concepts. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Over a one- to two-year period, readers are updated on all the major advances in allergy and asthma.